BlackRock
ACET icon

BlackRock’s Adicet Bio ACET Stock Holding History

BlackRock’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$249K Hold
36,585
– – ﹤0.01% 4713
2025
Q4 		$308K Sell
36,585
-1
-0% -$11 ﹤0.01% 4610
2025
Q3 		$474K Sell
36,586
-882
-2% -$10.4K ﹤0.01% 4468
2025
Q2 		$366K Sell
37,468
-9,349
-20% -$98.6K ﹤0.01% 4519
2025
Q1 		$566K Sell
46,817
-3,919
-8% -$56K ﹤0.01% 4368
2024
Q4 		$781K Buy
50,736
+3,735
+8% +$70.5K ﹤0.01% 4287
2024
Q3 		$1.08M Sell
47,001
-16,590
-26% -$371K ﹤0.01% 4156
2024
Q2 		$1.23M Sell
63,591
-147,236
-70% -$3.95M ﹤0.01% 4121
2024
Q1 		$7.93M Buy
210,827
+74,410
+55% +$3.08M ﹤0.01% 3465
2023
Q4 		$4.13M Sell
136,417
-5,425
-4% -$118K ﹤0.01% 3761
2023
Q3 		$3.11M Sell
141,842
-7,390
-5% -$261K ﹤0.01% 3854
2023
Q2 		$5.8M Sell
149,232
-9,318
-6% -$822K ﹤0.01% 3663
2023
Q1 		$14.6M Sell
158,550
-551
-0.3% -$69.1K ﹤0.01% 3121
2022
Q4 		$22.8M Buy
159,101
+27,239
+21% +$6.8M ﹤0.01% 2959
2022
Q3 		$30M Buy
131,862
+16,294
+14% +$4.14M ﹤0.01% 2796
2022
Q2 		$27M Buy
115,568
+14,436
+14% +$3.17M ﹤0.01% 2914
2022
Q1 		$32.3M Buy
101,132
+10,354
+11% +$2.38M ﹤0.01% 2858
2021
Q4 		$25.4M Buy
90,778
+12,746
+16% +$2.19M ﹤0.01% 3137
2021
Q3 		$9.79M Buy
78,032
+825
+1% +$102K ﹤0.01% 3680
2021
Q2 		$12.7M Buy
77,207
+46,605
+152% +$9.49M ﹤0.01% 3556
2021
Q1 		$6.4M Buy
30,602
+13,448
+78% +$3.09M ﹤0.01% 3827
2020
Q4 		$3.86M Buy
17,154
+8,775
+105% +$1.8M ﹤0.01% 3805
2020
Q3 		$1.59M Sell
8,379
-647
-7% -$164K ﹤0.01% 3963
2020
Q2 		$2.17M Sell
9,026
-5,097
-36% -$1M ﹤0.01% 3804
2020
Q1 		$1.63M Buy
14,123
+349
+3% +$51.8K ﹤0.01% 3718
2019
Q4 		$2.3M Buy
13,774
+1,082
+9% +$548K ﹤0.01% 3746
2019
Q3 		$12.6M Buy
12,692
+337
+3% +$376K ﹤0.01% 3101
2019
Q2 		$14.1M Buy
12,355
+5,207
+73% +$4.72M ﹤0.01% 3042
2019
Q1 		$5.46M Sell
7,148
-19
-0.3% -$17.3K ﹤0.01% 3377
2018
Q4 		$6.92M Buy
7,167
+2,968
+71% +$3.91M ﹤0.01% 3273
2018
Q3 		$7.12M Buy
4,199
+1,339
+47% +$1.75M ﹤0.01% 3381
2018
Q2 		$2.93M Buy
2,860
+198
+7% +$213K ﹤0.01% 3622
2018
Q1 		$2.86M Buy
+2,662
New +$4.88M ﹤0.01% 3583

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock's ACET Position: Q1 2026 in Review

BlackRock held its Adicet Bio (ACET) position steady in Q1 2026 at 36,585 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #4713.

BlackRock first reported a position in ACET in Q1 2018 and has held it in 33 quarters since. The position peaked at $32.3M in Q1 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • BlackRock held 36,585 shares of Adicet Bio worth $249K as of Q1 2026.
  • BlackRock left its Adicet Bio share count unchanged in Q1 2026.
  • Adicet Bio made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4713 holding.
  • BlackRock first reported a position in Adicet Bio in Q1 2018 and has held it in 33 quarters since.
  • BlackRock's Adicet Bio position peaked at $32.3M in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.